Dexcom Inc. has announced the official launch of Stelo, its new over-the-counter continuous glucose monitor (CGM), now available for purchase in the U.S. This device, designed for individuals with prediabetes or Type 2 diabetes who do not use insulin, as well as those without these conditions, represents a significant advancement in accessible glucose monitoring.
Stelo, which was approved by the U.S. Food and Drug Administration (FDA) in March, is the first over-the-counter CGM to receive clearance. It allows users to monitor their glucose levels continuously through a small, quarter-sized sensor worn on the upper arm. The device lasts for 15 days and transmits data wirelessly to a smartphone app. Users can purchase a one-month supply for $99 or opt for a subscription service at $89 per month. Flexible Spending Accounts and Health Savings Accounts can be used to cover costs, according to Dexcom.
Jake Leach, Dexcom’s Chief Operating Officer, emphasized that Stelo aims to educate users about how their dietary choices and habits affect glucose levels. “The idea is to help people, over time, learn about diet choices and habits and how those are impacting glucose,” Leach told CNBC. The app provides real-time glucose readings, updates every 15 minutes, and visualizes data to help users maintain their glucose within a target range, which is typically between 70 and 180 mg/dL as per American Diabetes Association standards.
Stelo alerts users to significant glucose spikes, which are crucial for preventing potential health issues such as diabetes and cardiovascular disease. The app also features a “Learn” tab with educational resources on glucose management and healthy habits.
Dexcom is collaborating with Amazon for Stelo deliveries, which are scheduled at 30-day intervals for subscription users. This launch marks Dexcom’s entry into the prediabetes market, expanding its reach beyond its traditional Type 1 and Type 2 diabetes patient base.
Read More: Click Here
